News
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Zacks Investment Research on MSN7d
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...
Zacks Investment Research on MSN20d
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company’s key top-line drivers. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback